key: cord-0025285-582ts5mf
authors: Tabak, Ying P.; Sun, Xiaowu; Brennan, Troyen A.; Chaguturu, Sreekanth K.
title: Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021
date: 2021-12-22
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.43346
sha: c6962548361cc8dd907878538a83a4a70cc9a547
doc_id: 25285
cord_uid: 582ts5mf

This case-control study evaluates the estimated vaccine effectiveness against infection changes over time to help inform public health policy and clinical practices.

screening questions were asked before a test can be scheduled. Individuals could also walk into the test sites where the same screening questions were answered on site before nasal swabs were collected. The collected specimens were sent to commercial laboratories contracted with CVS Health for the RT-PCR test. The test results were uploaded to MyChart where persons tested could login and check the results. Persons with rapid SARS-CoV-2 antigen tests were excluded.

A limited retrospective dataset from May 1 through August 7, 2021 was used for this study. The study protocol was approved by the Sterling IRB and the waiver of informed consent was granted because this is a retrospective analysis of existing data.

The test screening questionnaire included demographics, a list of self-reported symptoms per CDC's guideline: fever, shortness of breath, cough, chill, nausea or vomiting, muscle pain, sore throat, loss of taste or smell, fatigue, headache, congestion, diarrhea. It also asked self-reported vaccination received prior to the testing date at any site (not just CVS sites) including number of doses, manufacturer, and date of vaccination.

We used a test-negative case-control design (TND) to conduct a retrospective study to estimate vaccine effectiveness (VE) against SARS-CoV-2 infection during specified intervals postvaccination. The TND was used to compare the odds of testing positive for SARS-CoV-2 infection among vaccinees with the odds among unvaccinated persons. This design helps address healthcare-seeking behavioral bias since both test positive cases and test negative controls were symptomatic and seeking testing. The TND is widely used in post-licensure assessments of vaccine effectiveness. [1] [2] [3] [4] [5] 

Unique adult persons (18 years or older) who were tested during May 1 through August 7, 2021 at any CVS SARS-CoV-2 test site and reported at least one symptom were included. We 

We reported SARS-CoV-2 infection incidence rate by the week of test stratified by vaccination status. We overlayed the CDC reported proportion of delta variant in the US by week from June 1 to August 7 (https://covid.cdc.gov/covid-data-tracker/#variant-proportions) to evaluate the trend of incidence rate in relation to the delta variant. We conducted a sensitivity analysis by 

Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant

Influenza vaccine effectiveness in the United States during the 2015-2016 Season

Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review

The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings

Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a testnegative design